Aradigm Corp. (NASDAQ:ARDM) Given $26.00 Average Price Target by Analysts
Aradigm Corp. (NASDAQ:ARDM) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $26.00 for the company, according to Zacks. Zacks has also given Aradigm Corp. an industry rank of 88 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of Aradigm Corp. from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday, August 24th.
Shares of Aradigm Corp. (NASDAQ:ARDM) traded down 0.96% on Wednesday, reaching $5.18. 5,447 shares of the company were exchanged. The company’s market capitalization is $76.57 million. Aradigm Corp. has a 52-week low of $2.60 and a 52-week high of $7.83. The stock has a 50 day moving average of $4.65 and a 200-day moving average of $4.48.
Aradigm Corp. (NASDAQ:ARDM) last issued its earnings results on Wednesday, August 10th. The company reported ($0.59) earnings per share for the quarter, hitting the consensus estimate of ($0.59). Aradigm Corp. had a negative net margin of 670.67% and a negative return on equity of 147.53%. On average, analysts predict that Aradigm Corp. will post ($1.92) EPS for the current fiscal year.
An institutional investor recently raised its position in Aradigm Corp. stock. Paulson & CO. Inc. raised its stake in shares of Aradigm Corp. (NASDAQ:ARDM) by 235.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,903 shares of the company’s stock after buying an additional 46,241 shares during the period. Paulson & CO. Inc. owned approximately 0.45% of Aradigm Corp. worth $288,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.27% of the company’s stock.
Aradigm Corp. Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corp. and related companies with MarketBeat.com's FREE daily email newsletter.